Products
Omalizumab is commercially available as a powder and solvent for solution for injection (Xolair). It has been approved in many countries since 2006.
Structure and properties
Omalizumab is a recombinant, humanized monoclonal antibody with a molecular weight of approximately 149 kDa.
Effects
Omalizumab (ATC R03DX05) has antiallergic and antiasthmatic properties. The effects are based on selective binding of the antibody to immunoglobulin E (IgE) and interruption of the allergic response.
Indications
- As a 2nd-line agent in combination with other antiasthmatics for severe and persistent allergic asthma.
- Chronic spontaneous urticaria (new approval in the EU, 2014).
Dosage
According to the professional information. The drug is administered subcutaneously on the upper arm in the deltoid region or alternatively in the thigh every 2 to 4 weeks under medical treatment. Do not inject intravenously or intramuscularly!
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Drug-drug interactions have not been reported to date. The effects of anthelmintics may be indirectly reduced by the development of worm infections while on treatment.
Adverse effects
The most common potential adverse effects include fever, headache, upper abdominal pain, and pain, redness, itching, and swelling at the injection site. Rarely, severe and potentially life-threatening anaphylaxis is possible.
